Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The study, funded by the National Institutes of Health, supports no change to surgical technique for trichiasis management.

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...

The FDA's approval was based on three studies involving over 1,000 patients with moderate-to-severe eczema who were unable to ...

The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...

By Hector MacKenzie via SWNS A mom is raising awareness by sharing pictures of her eleven-year-old daughter's eczema - which ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

Eli Lilly said the Food and Drug Administration approved its treatment for moderate-to-severe eczema that isn't well controlled despite treatment with topical prescription therapies.

Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...